Seek Returns

NVO vs. RVTY: Novo Nordisk vs. Revvity Stock Comparison

How do Novo Nordisk (NVO) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Novo Nordisk (NVO) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while RVTY is classified in Life Sciences Tools & Services.

Revvity (RVTY) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Novo Nordisk (NVO) and Revvity (RVTY)
Profile ItemNVORVTY
NameNovo Nordisk A/S Sponsored ADRRevvity Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsLife Sciences Tools & Services
GICS Sub-IndustryPharmaceuticalsLife Sciences Tools & Services
Market Capitalization177.74 billion USD17.31 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateApril 30, 1981February 21, 1973
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

NVO
RVTY
GSPC
Loading price history…
Novo Nordisk (NVO) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Novo Nordisk (NVO) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Novo Nordisk (NVO) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Total Return (1Y)-5.29%76.75%
Total Return (3Y, Annualized)-23.41%24.22%
Total Return (5Y, Annualized)-4.13%-1.48%

Risk Profile

Drawdown History

NVO
RVTY
GSPC
Loading price history…
Novo Nordisk (NVO) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Novo Nordisk (NVO) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Volatility (1Y, Annualized)45.98%40.22%
Beta (5Y)0.671.07
Max Drawdown (5Y)-74.70%-59.01%
Avg. Volume (3M)12.11M1.89M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
NVO and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Sharpe Ratio (1Y)-0.211.80
Sortino Ratio (1Y)-0.282.90

Profitability

ROE (TTM)

Novo Nordisk (NVO) at 58.38% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for NVO.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

58.38%

Max
109.18%
NVO
58.38%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Novo Nordisk (NVO) at 33.92% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.92%

NVO
33.92%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Novo Nordisk (NVO) at 40.05% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.05%

Max
83.12%
NVO
40.05%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
ROE (TTM)58.38%3.45%
ROA (TTM)19.05%2.54%
Net Margin (TTM)33.92%8.61%
Operating Margin (TTM)40.05%17.06%
Gross Margin (TTM)83.33%55.91%

Growth

Revenue Growth

Both Novo Nordisk (NVO) at 6.43% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Novo Nordisk (NVO) at 1.77% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Revenue Growth (YoY)6.43%3.67%
Revenue Growth (3Y CAGR)20.43%-4.82%
EPS Growth (YoY)1.77%-5.91%
EPS Growth (3Y CAGR)23.52%-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.85

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
NVO
0.85
Min
0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Novo Nordisk (NVO) at 0.62 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.62

Max
1.42
Q3
0.65
NVO
0.62
Median
0.15
Q1
0.02
Min
0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Current Ratio (MRQ)0.852.65
Debt / Equity (MRQ)0.620.38
Net Debt / EBITDA0.492.43

Dividends

Dividend Yield (TTM)

Both Novo Nordisk (NVO) at 29.03% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.03%

NVO
29.03%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Novo Nordisk (NVO) at 45.36% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.36%

NVO
45.36%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
Dividend Yield (TTM)29.03%0.19%
Dividend Payout Ratio (TTM)45.36%13.40%

Valuation

P/E Ratio (TTM)

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Revvity (RVTY) at 68.94 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.18

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
NVO
10.18
Min
0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Revvity (RVTY) at 5.88 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.53

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
NVO
0.53
Min
0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

NVO

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.43

Max
13.53
Q3
6.54
NVO
5.43
Median
3.25
Q1
1.69
Min
-5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59
Loading chart…
Novo Nordisk (NVO) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Novo Nordisk (NVO) and Revvity (RVTY)
MetricNVORVTY
P/E Ratio (TTM)10.1868.94
P/S Ratio (TTM)0.535.88
P/B Ratio (MRQ)5.432.39
Free Cash Flow Yield (TTM)18.43%3.62%